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 Abstract 
HIV-associated Guillain-Barré Syndrome is a well-documented phenomenon, typically 
occurring at seroconversion. GBS may result in functional impairment treated with a 
combination of medications, plasmapheresis, and rehabilitation.  The quantified 
functional recovery of HIV-associated GBS with or without HIV treatment is not well-
described.  Utilizing serial FIM scoring, we describe a patient’s recovery from HIV-
associated GBS after treatment with IVIg and acute inpatient rehabilitation without HIV 
treatment.   
 





Standard Guillain-Barré Syndrome (sGBS) is an autoimmune disorder characterized by 
sudden onset of weakness with evidence of demyelination through electrodiagnosis.1  
This condition often requires pharmacological and/or plasmapheresis treatment.  After 
treatment, 40% of sGBS  patients require inpatient rehabilitation.2  The most rapid 
improvement is the first 6 months.3  sGBS recovers during the first year of onset, motor 
improvements at 18 months, but motor and sensory impairments are detectable in more 
than 50% of patients at two years.4  Functional Independence Measure (FIMTM) is a 
proven tool to monitor rehabilitation progress of sGBS.5   
 
There are several peripheral neuropathies associated with HIV.6  HIV-associated GBS 
(hGBS) is well documented.7,8,9  which may occur during the entire course of the disease, 
but typically occurs at seroconversion,10,11,12  but may  Quinn’s states “neurological 
impairment [from HIV] is generally self-limited; most patients become asymptomatic in 
1 to 4 weeks, although persistent neurologic deficits have been described.”13  Recent 
literature describes prolonged recovery of HIV-related chronic neurologic conditions. 10  
Verma speculates that the clinical course and response to pharmacologic treatment for 
GBS in HIV-seropositive and seronegative patients is similar14, but the functional 
recovery of hGBS with or without HIV treatment is not well described.  We describe a 
case of hGBS without HIV treatment with subacute recovery.   
Case report 
 
A 45-year-old woman presented with left sided weakness after 10 days of headache with 
nausea and vomiting and an inability to ambulates.  CT and MRI of the brain and spine 
were unremarkable.  She refused lumbar puncture.  Electrodiagnostic studies revealed 
demyelinating sensorimotor polyneuropathy without denervation.  Diagnosed with 
Guillain-Barré Syndrome (GBS), she was treated with IVIG, and discharged to inpatient 
rehabilitation.   
 
On admission, her initial exam revealed areflexia with intact sensation to light touch and 
pinprick.  There were no symptoms of dysautonomia but dysesthesias were present in her 
bilateral hands.  Manual muscle testing revealed grade 5-/5 humeral abductors, 4/5 elbow 
flexors/extensors, wrist extensors, 3+/5 flexor digitorum profundi, 2/5 dorsal interossei,  
3/5 hip flexors,  4/5 knee extensors, and 4/5 ankle dorsi/plantar flexors bilaterally.15  
Functional Independent Measure (FIMTM) scores showed functional deficit requiring 
moderate assistance for self care, minimal assistance for sphincter control, and 
dependence for ambulation (Table 1).  She initially made gains but then experienced 
progressive weakness and decline in many functional domains (Table 1). 
 
Work-up included a second electrodiagnostic study approximately 1 month after initial 
study, revealing more evidence of a demyelinating polyneuropathy (Table 2): severe 
distal motor latency prolongation and abnormal distal temporal dispersion (duration >9.0 
ms) in motor nerves.  Left peroneal and right median abnormal proximal temporal 
dispersion.  Sural responses were present with attenuated amplitudes.  No conduction 
blocks or demyelinating F-waves (absent F-waves with relatively normal CMAP 
amplitude, or severely prolonged F-wave minimal latencies) were noted.  EMG revealed 
denervation suggestive of secondary axonal injury.  Lumbar puncture had elevated 
protein 240mg (normal value 15-55) and cell count of 39WBC & 8RBC with normal 
glucose 53mg/dL (normal value 40-70).  Because of elevated CSF cell count and protein, 
further work revealed positive HIV ELISA and confirmed by western blot.  CD4 count of 
334cells/ml (normal value 410-1590) and viral load 394,000copies/ml (normal value 
<400).   
 
Rehabilitation was reinitiated without further pharmacological treatment for GBS or HIV.    
Due to concern for compliance, infectious disease consultant did not treat HIV.  One 
month after readmission she displayed functional improvement at supervision for most 
self care domains, independence with sphincter control, modified independent for 
mobility at a wheel chair level (Table 1).  Her exam on discharge revealed symmetric 1+ 
reflexes with sensation intact to light touch and pinprick.  Manual muscle testing revealed 
4+-5/5 strength in all muscle groups.  Three months after discharge and five months after 
onset of hGBS, she had complete functional recovery; independent in all FIMTM domains 
including ambulation without assistive device (see Table 1).  She was lost to further 
follow-up.    
Discussion 
We present a case of GBS occurring as the first manifestation of HIV infection and her 
functional recovery after IVIG and inpatient rehabilitation which suggests that hGBS 
patients may make full subacute recovery without the initiation of HAART therapy.  To 
our knowledge, there are no reports of acute seroconverted hGBS rehabilitation recovery 
without HIV treatment.  This may add to the controversy in the literature regarding hGBS 
treatment with HAART with both relapse16 upon discontinuation or cause due to drug 
side effect or of HAART or potentially cause via immune reconstitution syndrome.17 
 
Neurologic impairment related to HIV are recognized have prolonged recovery at best.13, 
18
  Our case presents hGBS taking 5 months full functional recovery.  This is timely as 
compared to the described recovery of sGBS and confirms Verma’s speculation.14 
 
Limitations of this manuscript include the use of FIMTM scoring to quantify functional 
recovery, as there are other tools to evaluate recovery of GBS patients.19 Additionally, 





We present a case of Guillain-Barré Syndrome as the initial clinical manifestation of HIV 
infection.  With standard GBS treatment, without HIV treatment, the patient made similar 
functional recovery, quantified by FIMTM scoring, that is described for sGBS.  Further 
research is needed on the recovery of HIV-associated GBS with various treatment 
strategies so physicians can better prognosticate functional recovery. 
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